NewsBenzingaElicio Therapeutics、ESMO Congress 2026で第2相AMPLIFY-7P試験の速報結果を発表;複数の事前規定サブグループ解析でカムペピムットが優位、ベースラインで検出可能なctDNAの有無を問わず患者で有利な結果を示す;ctDNA陰性・陽性の両患者で良好な無病生存期間の成績を確認 Elicio Therapeutics、ESMO Congress 2026で第2相AMPLIFY-7P試験の速報結果を発表;複数の事前規定サブグループ解析でカムペピムットが優位、ベースラインで検出可能なctDNAの有無を問わず患者で有利な結果を示す;ctDNA陰性・陽性の両患者で良好な無病生存期間の成績を確認 Benzinga 2026.10.23 13:07 (GMT+0) Open on Benzinga Other news Here's How Much $1000 Invested In Analog Devices 20 Years Ago Would Be Worth Today RPC Says Richard A. Hubbell To Retire As Executive Chairman And Director Effective Dec 31, 2026 Neocloud Stocks Catch a Bid After Nvidia Q3 Beat NVIDIA Interim CEO Says Co.'s Q4 Sales Growth To Be Driven By AI Demand, Vera Rubin Rollout NVIDIA Interim CEO Says Co. Remains On Track To Launch Vera Rubin Ultra Next Year And Feynman In 2028 ReAlpha Tech Corp Q3 EPS $(0.60) Misses $(0.50) Estimate, Sales $1.604M Miss $5.644M Estimate
NVIDIA Interim CEO Says Co. Remains On Track To Launch Vera Rubin Ultra Next Year And Feynman In 2028